World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
144
Citations
90270
World Ranking
1429
National Ranking
16

Overview

Heikki Joensuu is affiliated with the University of Helsinki in Finland and has an extensive research portfolio primarily in the fields of Medicine and Biochemistry, Genetics and Molecular Biology. Their scientific contributions span various subfields including Oncology, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging, Cancer Research, and Gastroenterology.

Their research topics cover multiple areas relevant to cancer biology and treatment, including HER2/EGFR in Cancer Research, Gastrointestinal Tumor Research and Treatment, Prostate Cancer Treatment and Research, Gastric Cancer Management and Outcomes, Cancer Immunotherapy and Biomarkers, Monoclonal and Polyclonal Antibodies Research, and Breast Cancer Treatment Studies.

Joensuu's recent publications include:

  • FinnGen provides genetic insights from a well-phenotyped isolated population, 2023, Nature
  • Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up, 2021, Annals of Oncology
  • Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up, 2021, Annals of Oncology
  • FinnGen: Unique genetic insights from combining isolated population and national health register data, 2022, bioRxiv (Cold Spring Harbor Laboratory)
  • Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up, 2021, Annals of Oncology

Frequent co-authors working with Joensuu include:

  • Karim Fizazi
  • Iris Kuss
  • Peter Hohenberger
  • Sebastian Bauer
  • Mikael Eriksson

The main publication venues for Joensuu's work are diverse but show strong presence in oncology and clinical research journals. These include:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Cancer Research
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Acta Oncologica

Joensuu's research output reflects a focus on clinical guidelines and molecular insights into cancer types including sarcomas and gastrointestinal tumors, with significant engagement in combining population genetics with disease phenotyping to improve understanding of cancer etiology and treatment outcomes.

Best Publications

  • Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

    George Daniel Demetri;Margaret von Mehren;Charles D. Blanke;Annick Diane Van Den Abbeele

  • Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor

    Michael C. Heinrich;Christopher L. Corless;George D. Demetri;Charles D. Blanke

  • Effect of the Tyrosine Kinase Inhibitor STI571 in a Patient with a Metastatic Gastrointestinal Stromal Tumor

    Heikki Joensuu;Peter J. Roberts;Maarit Sarlomo-Rikala;Leif C. Andersson

  • Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.

    Heikki Joensuu;Pirkko-Liisa Kellokumpu-Lehtinen;Petri Bono;Tuomo Alanko

  • Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

    George D Demetri;Peter Reichardt;Yoon-Koo Kang;Jean-Yves Blay

  • Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

    S. Loi;S. Loi;S. Michiels;S. Michiels;R. Salgado;N. Sirtaine

  • Risk stratification of patients diagnosed with gastrointestinal stromal tumor

    Heikki Joensuu

  • Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†

    P.G. Casali;N. Abecassis;S. Bauer;R. Biagini

  • Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT

    Charles D Blanke;George D Demetri;Margaret von Mehren;Michael C Heinrich

  • One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.

    Heikki Joensuu;Mikael Eriksson;Kirsten Sundby Hall;Jörg T. Hartmann

  • Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer.

    Ari Ristimäki;Anna Sivula;Johan Lundin;Mikael Lundin

  • NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.

    George D. Demetri;Robert S. Benjamin;Charles D. Blanke;Jean Yves Blay

  • Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts

    Heikki Joensuu;Aki Vehtari;Jaakko Riihimäki;Toshirou Nishida

  • Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal Tumors

    Michael C. Heinrich;Christopher L. Corless;Charles D. Blanke;George D. Demetri

  • Consensus meeting for the management of gastrointestinal stromal tumors Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO

    Jean Yves Blay;Sylvie Bonvalot;Paolo Casali;Haesun Choi

  • Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab

    M. Tanner;M. Hollmén;T. T. Junttila;A. I. Kapanen

  • Management of malignant gastrointestinal stromal tumours.

    Heikki Joensuu;Christopher Fletcher;Sasa Dimitrijevic;Sandra Silberman

  • VEGFR-3 and Its Ligand VEGF-C Are Associated with Angiogenesis in Breast Cancer

    Reija Valtola;Petri Salven;Päivi Heikkilä;Jussi Taipale

  • Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

    P.G. Casali;N. Abecassis;S. Bauer;R. Biagini

  • Consensus meeting for the management of gastrointestinal stromal tumors Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO (vol 16, pg 566, 2005)

    JY Blay;S Bonvalot;P Casali;H Choi

Frequent Co-Authors

George D. Demetri
George D. Demetri Dana-Farber Cancer Institute
Jorma Isola
Jorma Isola Tampere University
Peter Hohenberger
Peter Hohenberger Heidelberg University
Mikael Eriksson
Mikael Eriksson Karolinska Institute
Eero Pukkala
Eero Pukkala Tampere University
Paolo G. Casali
Paolo G. Casali University of Milan
Vesa Kataja
Vesa Kataja University of Eastern Finland
Hans Gelderblom
Hans Gelderblom Leiden University Medical Center
Hans H. Storm
Hans H. Storm Danish Cancer Society
Per Hall
Per Hall Karolinska Institute

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medicine in the USA opens doors to related healthcare degrees that offer flexible online options. Many professionals consider advancing their roles by pursuing a Master of Health Administration. For those seeking focused and industry-approved programs, cahme accredited online mha programs are an excellent choice, ensuring quality and recognition across the healthcare field.

Nurses aiming to upgrade their credentials often wonder, does rn to bsn require clinicals? Some online RN to BSN programs now provide flexible pathways, with limited or even no clinical requirements, making career advancement more accessible for working nurses.

Nurses and healthcare professionals interested in advanced practice and leadership may also consider accelerated degrees. Options like accelerated dnp programs and easiest dnp programs help busy professionals earn a Doctor of Nursing Practice at a faster pace or with reduced barriers.

Exploring these related online degrees can open new career pathways, offering flexibility and opportunities to make a greater impact in healthcare.

Best Scientists Citing Heikki Joensuu

Trending Scientists